Physician
Urology
Dr. Michael F. Sarosdy, MD
|
|
Give Review
Michael Sarosdy works in the field of Urology. He attended University of Texas Medical School. He received awards:"Super Doctor" and "Top MD". Michael Sarosdy is a published physician. He published 86 publications, including: 'Phase I clinical study of the recombinant oncotoxin TP40 in superficial bladder cancer.' Michael Sarosdy accepts Medicare payments and is registered with Medicare.gov.
Publications
- Testosterone Therapy after Radiation Therapy for Low, Intermediate and High Risk Prostate Cancer.
- Testosterone replacement for hypogonadism after treatment of early prostate Cancer with brachytherapy.
- Use of a multitarget fluorescence in situ hybridization assay to diagnose Bladder cancer in patients with hematuria.
- A phase II clinical trial of oral bropirimine in combination with intravesical bacillus Calmette-Guérin for carcinoma in situ of the Bladder: a Southwest ...
- Urinary and rectal complications of contemporary permanent transperineal brachytherapy for Prostate carcinoma with or without external beam radiation therapy.
- Surgical factors influence Bladder cancer outcomes: a cooperative group report.
- Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced Bladder cancer.
- Clinical evaluation of a multi-target fluorescent in situ hybridization assay for detection of Bladder cancer.
- Advanced Bladder cancer...where are we now and where are we going?
- Genetic fieldwork for hereditary prostate Cancer studies.
- Sector analysis of Prostate implants.
- Calibration, calculation, and prescription issues in permanent Prostate brachytherapy with (103)Pd.
- Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the Bladder: a randomized Southwest Oncolo...
- Does prolonged combined androgen blockade have survival benefits over short-term combined androgen blockade therapy?
- Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate Cancer.
- Which is the optimal antiandrogen for use in combined androgen blockade of advanced prostate Cancer? The transition from a first- to second-generation antiandrogen.
- Exploratory analysis on the effect of race on clinical outcome in patients with advanced prostate Cancer receiving bicalutamide or flutamide, each in combination with ...
- Endocrine effects, efficacy and tolerability of a 10.8-mg depot formulation of goserelin acetate administered every 13 weeks to patients with advanced prostate Cancer.
- Genetic pattern of prostate Cancer progression.
- Comparison of goserelin and leuprolide in combined androgen blockade therapy.
- Oral bropirimine immunotherapy of Bladder carcinoma in situ after prior intravesical bacille Calmette-Guérin.
- Data interpretation and integration of new tests into clinical practice.
- Improved detection of recurrent Bladder cancer using the Bard BTA stat Test.
- Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: final report of a double-blind,...
- Organization and expression of human telomere repeat binding factor genes.
- Long-term follow-up of patients with good-risk germ cell tumors treated with etoposide and cisplatin.
- The use of the BTA Test in the detection of persistent or recurrent transitional-cell cancer of the Bladder.
- A review of clinical studies of bropirimine immunotherapy of carcinoma in situ of the Bladder and upper urinary tract.
- Oral bropirimine immunotherapy of rodent prostate Cancer.
- The significance of central pathology review in clinical studies of transitional cell carcinoma in situ.
- Urinary nuclear matrix protein as a marker for transitional cell carcinoma of the urinary tract.
- Cautionary note on the use of dUMP-containing PCR primers with Pfu and VentR DNA polymerases.
- Use of a new tumor marker, urinary NMP22, in the detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment.
- Bropirimine immunotherapy of upper urinary tract carcinoma in situ.
- Oral bropirimine immunotherapy of carcinoma in situ of the Bladder: results of a phase II trial.
- In vivo antitumor activity of bropirimine against PAIII and Dunning MAT-LyLu rodent prostate Cancers.
- Additional experience with continent urinary diversion using cutaneous ileocecocystoplasty.
- A controlled trial of Casodex (bicalutamide) vs. flutamide, each in combination with luteinising hormone-releasing hormone analogue therapy in patients with advanced p...
- Maximal androgen blockade for patients with metastatic prostate Cancer: outcome of a controlled trial of bicalutamide versus flutamide, each in combination with lutein...
- Renal cell carcinoma metastatic to the gallBladder or prostate: two case reports.
- Raloxifene (LY156758) produces antimetastatic responses and extends survival in the PAIII rat prostatic adenocarcinoma model.
- The lack of predictive value of prostate specific antigen density in the detection of prostate Cancer in patients with normal rectal examinations and intermediate pros...
- Results of a multicenter trial using the BTA test to monitor for and diagnose recurrent Bladder cancer.
- Intestinal obstruction and bilateral ureteral injuries after laparoscopic oophorectomy in a patient with severe endometriosis.
- Percutaneous aortic stent placement for life threatening aortic rupture due to metastatic germ cell tumor.
- A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostat...
- Randomized intergroup comparison of bacillus calmette-guerin immunotherapy and mitomycin C chemotherapy prophylaxis in superficial transitional cell carcinoma of the b...
- Phase I clinical study of the recombinant oncotoxin TP40 in superficial Bladder cancer.
- Hormonal therapy for metastatic prostate Cancer: issues of timing and total androgen ablation.
- In vitro sensitivity testing of human Bladder cancers and cell lines to TP-40, a hybrid protein with selective targeting and cytotoxicity.
- Bropirimine in Bladder cancer: clinical studies.
- Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: a multiinstitutional study.
- Management of stage T1 superficial Bladder cancer with intravesical bacillus Calmette-Guerin therapy.
- Comparative antitumor effects of hormonal ablation, estrogen agonist, estrogen cytotoxic derivative, and antiestrogen in the PAIII rat prostatic adenocarcinoma.
- Principles of intravesical chemotherapy and immunotherapy.
- Continent urinary diversion using cutaneous ileocecocystoplasty.
- A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooper...
- High-dose versus low-dose intravesical interferon-alpha 2b in the treatment of carcinoma in situ: a randomized, controlled study.
- Management of the male urethra after cystectomy for Bladder cancer.
- Systematic transrectal ultrasound guided Prostate biopsy after negative digitally directed Prostate biopsy.
- Inhibition of PAIII rat prostatic adenocarcinoma growth and metastasis by a new diarylsulfonylurea antitumor agent, LY181984.
- Phase 1 trial of oral bropirimine in superficial Bladder cancer.
- A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guérin for transitional-cell carcinoma of the Bladder.
- Complications of the Heitz-Boyer urinary diversion: case report of late development of malignancy.
- Prospective randomized comparison of intravesical with percutaneous bacillus Calmette-Guerin versus intravesical bacillus Calmette-Guerin in superficial Bladder cancer.
- Phase I-II evaluation of intravesical novantrone (mitoxantrone) in superficial Bladder cancer.
- Fatal sepsis following intravesical bacillus Calmette-Guerin administration for Bladder cancer.
- A randomized prospective comparison of oral versus intravesical and percutaneous bacillus Calmette-Guerin for superficial Bladder cancer.
- Correlation of clonogenic growth with histologic diagnosis after resection of residual tissue following chemotherapy for nonseminomatous testis Cancer.
- Combination immunotherapy of murine transitional cell Cancer using BCG and an interferon-inducing pyrimidinone.
- Long-term results of intravesical bacillus Calmette-Guerin therapy for superficial Bladder cancer.
- A prospective double-blind trial of intracorporeal papaverine versus prostaglandin E1 in the treatment of impotence.
- Tumor-specific immunotherapy of murine Bladder cancer with butanol-extracted antigens and ethylchlorformate polymerized tumor protein.
- Urologic Cancer. Urologic Oncology Workgroup, Legislative Task Force on Cancer in Texas.
- A new technique for continent urinary diversion.
- In vitro chemosensitivity testing of human neuroblastoma cell lines in soft agar: a tumor-Specific drug screening model.
- Upper gastrointestinal bleeding following Renal transplantation.
- Hypercalcemia-induced upper gastrointestinal bleeding after Renal transplantation.
- Prediction of response to Cancer chemotherapy.
- Prospective clinical trial of a human tumor cloning system.
- Application of the mixed cell agglutination test for cell surface Antigens to renal cell carcinoma.
- Clonogenic assay and in vitro chemosensitivity testing of human urologic malignancies.
- Androgen priming and cytotoxic chemotherapy in advanced prostatic Cancer.
- Serum and bone marrow radioimmunoassay of acid phosphatase in prostatic Cancer.
- Scrotal actinomycosis.
Schools
Univ Of Tx Med Sch At San Antonio
University Of California San Diego
University Hawaii
University Tex
Procedures Preformed
- Cystometry
- Cystourethroscopy and Transurethral Resection of Bladder Neck
- Lithotripsy
- Orchiectomy
- View All
Conditions Treated
- Balanoposthitis
- Bladder Atony
- Bladder Cancer
- Bladder Infection
- View All
Doctors Specialties
- Urology
Accepted Insurances
Awards
- Super Doctor
- Top MD
Education
-
University of Texas Health Science Center -
University of California San Diego -
University of Texas Medical School
Drug Facts
| NPI NUMBER | 1649273442 | |
| NPPES Provider LastName | SAROSDY | |
| NPPES Provider FirstName | MICHAEL | |
| NPPES Provider ZIPCode | 782293712 | |
| NPPES Provider State | TX | |
| Specialty Description | Urology | |
| Total Claim Count | 1783.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 13.0 | |
| Percent Opioid Claims | 0.73 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1649273442 |
| Last Name Of The Provider | SAROSDY |
| First Name Of The Provider | MICHAEL |
| View All |
Similar Doctors
|
Dr. Patricia J. Terry, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Rene A. Sepulveda, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Thomas H. Bartholomew, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Leroy A. Jones, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Jeffrey A. Leslie, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Timothy Y. Tseng, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jerry E. Kruse, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Timothy C. Hlavinka, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jackie D. Stephenson, MD |
|
Dr. Andrew A. Tobon, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Peter A. Leininger, MD |
|
|
Dr. C R. Spence, MD |
|
|
Dr. Ian M. Thompson III, MD |
|
Dr. Christopher H. Cantrill, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. John P. Fitzgerald, MD |
|
|
Dr. Gustavo V. Villegas, MD |